Minireview: Androgen Metabolism in Castration-Resistant Prostate Cancer
Open accessThe DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.
Abstract
The decades-old terminology of androgen independence has been replaced in recent years with castration-resistant prostate cancer. Biological and clinical evidence have together conspired to support the use of this revised terminology by demonstrating that in the vast majority of cases tumors are neither truly depleted of androgens, nor are they free of the requirement for androgens to sustain growth and progression. Abiraterone acetate, an androgen synthesis inhibitor, and enzalutamide, a potent androgen receptor antagonist, both exploit the continued requirement for androgens. A central question, given the therapeutic gains enabled by further suppression of the androgen axis with these newer agents, is whether there may be additional clinical benefit gained by moving the goal posts of androgen suppression even further. The answer lies in part with the mechanisms utilized by tumors that enable resistance to these therapies. The aims of this review were to give a broad outline of steroidogenesis in prostate cancer and to highlight recent developments in understanding resistance to hormonal therapies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Abiraterone and Increased Survival in Metastatic Prostate Cancer
de Bono, J. S., Logothetis, C. J., Molina, A., Fizazi, K., North, S., Chu, L., Chi, K. N., Jones, R. J., Goodman, O. B., Saad, F., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1014618 · Cited by 4,407 · cited 2×
“The extension of survival conferred by agents that deplete intratumoral androgens serves as the most definitive evidence that androgen synthesis plays a central role in the progression of CRPC (20, 21).”
Recurrent Fusion of TMPRSS2 and ETS Transcription Factor Genes in Prostate Cancer
Tomlins, S. A., Rhodes, D. R., Perner, S., Dhanasekaran, S. M., Mehra, R., Sun, X.-W., Varambally, S., Cao, X., Tchinda, J., Kuefer, R., et al. (2005) · Science · doi:10.1126/science.1117679 · Cited by 3,846
Abiraterone in Metastatic Prostate Cancer without Previous Chemotherapy
Ryan, C. J., Smith, M. R., de Bono, J. S., Molina, A., Logothetis, C. J., de Souza, P., Fizazi, K., Mainwaring, P., Piulats, J. M., Ng, S., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1209096 · Cited by 2,796 · cited 2×
“The extension of survival conferred by agents that deplete intratumoral androgens serves as the most definitive evidence that androgen synthesis plays a central role in the progression of CRPC (20, 21).”
The Molecular Biology, Biochemistry, and Physiology of Human Steroidogenesis and Its Disorders
Miller, W. L., & Auchus, R. J. (2011) · Endocrine Reviews · doi:10.1210/er.2010-0013 · Cited by 2,458 · cited 11×
“The use of cholesterol for de novo steroidogenesis would require the same components of the steroidogenic machinery present in the adrenals and gonads, including steroidogenic acute regulatory protein, CYP11A1, and CYP17A1 (42), which may be operative in a model of prostate cancer (43).”
InfluentialDevelopment of a second-generation antiandrogen for treatment of advanced prostate cancer.
Tran, C., Ouk, S., Clegg, N. J., Chen, Y., Watson, P. A., Arora, V., Wongvipat, J., Smith-Jones, P. M., Yoo, D., Kwon, A., et al. (2009) · Science · doi:10.1126/science.1168175 · Cited by 2,292
Montgomery, R. B., Mostaghel, E. A., Vessella, R., Hess, D. L., Kalhorn, T. F., Higano, C. S., True, L. D., & Nelson, P. S. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-0249 · Cited by 1,419
Steroid 5α-reductase: two genes/two enzymes
Russell, D. W., & Wilson, J. D. (1994) · Annual Review of Biochemistry · doi:10.1146/annurev.bi.63.070194.000325 · Cited by 1,105
Stanbrough, M., Bubley, G. J., Ross, K., Golub, T. R., Rubin, M. A., Penning, T. M., Febbo, P. G., & Balk, S. P. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-4000 · Cited by 1,082
Scher, H. I., & Sawyers, C. L. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.03.4777 · Cited by 1,025 · cited 1×
“Heightened AR activity may be due to enhanced response of the receptor to a stimulus (eg, ligand sensitization) or due to increased expression, mutation, or other fundamental AR alteration (15).”
Locke, J. A., Guns, E. S., Lubik, A. A., Adomat, H. H., Hendy, S. C., Wood, C. A., Ettinger, S. L., Gleave, M. E., & Nelson, C. C. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-5997 · Cited by 747 · cited 1×
“The use of cholesterol for de novo steroidogenesis would require the same components of the steroidogenic machinery present in the adrenals and gonads, including steroidogenic acute regulatory protein, CYP11A1, and CYP17A1 (42), which may be operative in a model of prostate cancer (43).”
The Androgen Axis in Recurrent Prostate Cancer
Mohler, J. L., Gregory, C. W., Ford, O. H., Kim, D., Weaver, C. M., Petrusz, P., Wilson, E. M., & French, F. S. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-1146-03 · Cited by 675
Deletion of steroid 5α-reductase 2 gene in male pseudohermaphroditism
Andersson, S., Berman, D. M., Jenkins, E. P., & Russell, D. W. (1991) · Nature · doi:10.1038/354159a0 · Cited by 643
Molecular biology of the 3β-hydroxysteroid dehydrogenase/Δ5-Δ4 –isomerase gene family
Simard, J., Ricketts, M.-L., Gingras, S., Soucy, P., Feltus, F. A., & Melner, M. H. (2005) · Endocrine Reviews · doi:10.1210/er.2002-0050 · Cited by 620
Attard, G., Reid, A. H. M., A'Hern, R., Parker, C., Oommen, N. B., Folkerd, E., Messiou, C., Molife, L. R., Maier, G., Thompson, E., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.20.0642 · Cited by 605
Testosterone and Dihydrotestosterone Tissue Levels in Recurrent Prostate Cancer
Titus, M. A., Schell, M. J., Lih, F. B., Tomer, K. B., & Mohler, J. L. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-0525 · Cited by 488 · cited 3×
“A quarter century later, locally recurrent CRPC tissues were again assessed for intratumoral androgen concentrations, this time using mass spectrometry (17).”
Danila, D. C., Morris, M. J., de Bono, J. S., Ryan, C. J., Denmeade, S. R., Smith, M. R., Taplin, M.-E., Bubley, G. J., Kheoh, T., Haqq, C., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.25.9259 · Cited by 410
Ryan, C. J., Smith, M. R., Fong, L., Rosenberg, J. E., Kantoff, P., Raynaud, F., Martins, V., Lee, G., Kheoh, T., Kim, J., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.24.1281 · Cited by 396
Reid, A. H. M., Attard, G., Danila, D. C., Oommen, N. B., Olmos, D., Fong, P. C., Molife, L. R., Hunt, J., Messiou, C., Parker, C., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.24.6819 · Cited by 394
Potter, G. A., Barrie, S. E., Jarman, M., & Rowlands, M. G. (1995) · Journal of Medicinal Chemistry · doi:10.1021/jm00013a022 · Cited by 379
The backdoor pathway to dihydrotestosterone
Auchus, R. J. (2004) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2004.09.004 · Cited by 347 · cited 1×
“17 -hydroxyprogesterone) instead of a 19-carbon androgen (Figure 1) (47, 48).”
Dihydrotestosterone synthesis bypasses testosterone to drive castration-resistant prostate cancer
Chang, K.-H., Li, R., Papari-Zareei, M., Watumull, L., Zhao, Y. D., Auchus, R. J., & Sharifi, N. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1107898108 · Cited by 346
Self-citationGenetics of congenital adrenal hyperplasia
Krone, N., & Arlt, W. (2009) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2008.10.014 · Cited by 312
Cantagrel, V., Lefeber, D. J., Ng, B. G., Guan, Z., Silhavy, J. L., Bielas, S. L., Lehle, L., Hombauer, H., Adamowicz, M., Swiezewska, E., et al. (2010) · Cell · doi:10.1016/j.cell.2010.06.001 · Cited by 309
Novel 5α‐steroid reductase (SRD5A3, type‐3) is overexpressed in hormone‐refractory prostate cancer
Uemura, M., Tamura, K., Chung, S., Honma, S., Okuyama, A., Nakamura, Y., & Nakagawa, H. (2008) · Cancer Science · doi:10.1111/j.1349-7006.2007.00656.x · Cited by 263
Persistent Intraprostatic Androgen Concentrations after Medical Castration in Healthy Men
Page, S. T., Lin, D. W., Mostaghel, E. A., Hess, D. L., True, L. D., Amory, J. K., Nelson, P. S., Matsumoto, A. M., & Bremner, W. J. (2006) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2006-0968 · Cited by 229 · cited 1×
“Nonetheless, studies assessing intraprostatic concentrations of T and DHT after the initiation of ADT have shown that androgens in benign prostate and prostate cancer are far from deplete (10, 11).”
Integrated view on 17beta-hydroxysteroid dehydrogenases
Moeller, G., & Adamski, J. (2009) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2008.10.040 · Cited by 214
Evidence of limited contributions for intratumoral steroidogenesis in prostate cancer
Hofland, J., van Weerden, W. M., Dits, N. F. J., Steenbergen, J., van Leenders, G. J. L. H., Jenster, G., Schröder, F. H., & de Jong, F. H. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-2092 · Cited by 176 · cited 1×
“Other studies have instead described limited expression of transcripts encoding both CYP17A1 and 3 HSD1, which are both required for de novo steroidogenesis, in metastatic tumors (45).”
Androgen biosynthetic pathways in the human prostate
Luu-The, V., Bélanger, A., & Labrie, F. (2008) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2008.01.008 · Cited by 169 · cited 1×
“There are 2 possible pathways from adrenal precursor steroids to DHT (5, 49).”
Thigpen, A. E., Cala, K. M., & Russell, D. W. (1993) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(19)85349-8 · Cited by 152
Thomas, J. L., Mason, J. I., Brandt, S., Spencer, B. R., & Norris, W. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m208537200 · Cited by 115
Prostate formation in a marsupial is mediated by the testicular androgen 5α-androstane-3α,17β-diol
Shaw, G., Renfree, M. B., Leihy, M. W., Shackleton, C. H. L., Roitman, E., & Wilson, J. D. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.220412297 · Cited by 101
Molecular Pathways: Inhibiting Steroid Biosynthesis in Prostate Cancer
Ferraldeschi, R., Sharifi, N., Auchus, R. J., & Attard, G. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-0931 · Cited by 93
Self-citationSRD5A3: a surprising role in glycosylation
Stiles, A. R., & Russell, D. W. (2010) · Cell · doi:10.1016/j.cell.2010.07.003 · Cited by 66
The 5α-androstanedione pathway to dihydrotestosterone in castration-resistant prostate cancer
Sharifi, N. (2012) · Journal of Investigative Medicine · doi:10.2310/jim.0b013e31823874a4 · Cited by 52
Self-citation
Cited by
Mechanisms of resistance in castration-resistant prostate cancer (CRPC).
Chandrasekar, T., Yang, J. C., Gao, A. C., & Evans, C. P. (2015) · PubMed · doi:10.3978/j.issn.2223-4683.2015.05.02 · Cited by 514
A Gain-of-Function Mutation in DHT Synthesis in Castration-Resistant Prostate Cancer
Chang, K.-H., Li, R., Kuri, B., Lotan, Y., Roehrborn, C. G., Liu, J., Vessella, R., Nelson, P. S., Kapur, P., Guo, X., et al. (2013) · Cell · doi:10.1016/j.cell.2013.07.029 · Cited by 312
Self-citation11-Oxygenated androgens in health and disease
Turcu, A. F., Rege, J., Auchus, R. J., & Rainey, W. E. (2020) · Nature Reviews Endocrinology · doi:10.1038/s41574-020-0336-x · Cited by 217
Sex hormones and prostate cancer
Auchus, R. J., & Sharifi, N. (2020) · Annual Review of Medicine · doi:10.1146/annurev-med-051418-060357 · Cited by 85
Self-citation
Metadata
- Authors
- Sharifi, N.
- Venue
- Molecular Endocrinology
- Publisher
- The Endocrine Society
- Published
- 2013-05-01
- Volume
- 27
- Issue
- 5
- Pages
- 708-714
- ISSN
- 0888-8809 (ISSN-L)
- 1944-9917
- OpenAlex
- W2052964297
- Cited by
- 76
- References
- 34
- FWCI
- 7.06
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.